MARKET

SLS

SLS

Sellas Life Sciences Group Inc
NASDAQ
12.62
-0.14
-1.10%
After Hours: 12.57 -0.05 -0.40% 17:50 07/13 EDT
OPEN
12.46
PREV CLOSE
12.76
HIGH
12.99
LOW
12.33
VOLUME
5.15M
TURNOVER
--
52 WEEK HIGH
15.88
52 WEEK LOW
1.390
MARKET CAP
2.48B
P/E (TTM)
-54.2562
1D
5D
1M
3M
1Y
5Y
1D
Noteworthy Monday Option Activity: SLS, MCRI, ALK
NASDAQ · 2h ago
Weekly Report: what happened at SLS last week (0706-0710)?
Weekly Report · 12h ago
Sellas Life Sciences: REGAL Trial's Delayed Events Signal Selection Bias
Seeking Alpha · 4d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (BMY) and SELLAS Life Sciences Group (SLS)
TipRanks · 4d ago
SELLAS Life Sciences Shares Slip Wednesday as Price Tests $16 Resistance Wall
Benzinga · 5d ago
SELLAS LIFE SCIENCES GROUP INC <SLS.O>: MAXIM GROUP RAISES TARGET PRICE TO $30 FROM $10
Reuters · 5d ago
This Little-Known Stock Has Surged 550% in the Past Year
Barchart · 07/06 11:40
Sellas Life Sciences price target raised to $25 from $10 at Alliance Global
TipRanks · 07/06 11:05
More
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.

Webull offers Sellas Life Sciences Group Inc stock information, including NASDAQ: SLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLS stock methods without spending real money on the virtual paper trading platform.